Scholar Rock Holding

Scholar Rock is a clinical-stage biopharmaceutical company founded on a paradigm-shifting scientific strategy: targeting the latent, inactive forms of growth factors, particularly within the TGFβ superfamily, to achieve precise, localized therapeutic effects. The company's most advanced asset, apitegromab, has demonstrated promising Phase 3 results in spinal muscular atrophy (SMA) and is positioned as a potential first-in-class muscle-targeted therapy. Supported by a robust proprietary platform and a strong financial position, Scholar Rock's strategy extends beyond neuromuscular diseases into cardiometabolic disorders and immuno-oncology, aiming to build a diversified portfolio of novel biologics.

Proprietary platform for developing biologics that selectively target the activation of latent growth factors (e.g., TGFβ superfamily) in the disease microenvironment, aiming for localized inhibition and improved therapeutic indices.

In SMA, apitegromab competes for adjunctive use against established SMN-upregulating therapies. Its latent-targeting selectivity is a key differentiator from other muscle-targeting approaches. In oncology, SRK-181's latent-specific TGFβ1 inhibition aims to avoid systemic toxicities that have plagued broader TGFβ inhibitors, positioning it uniquely in a competitive I/O space.